Stay updated on our upcoming events, participation at exhibitions, interesting publications and other news.
December 10, 2021
Therapeutic Immunoglobulins – Rox Factor XIa evaluated by NIBSC for detection of low levels of FXIa
September 24, 2020
Collaboration with BioMarin – Study on FVIII gene therapy assay discrepancy now published in Blood!
We have been working with BioMarin in order to identify a cause of dicrepancy between one stage assays and chromogenic assays when analysing transgene-produced FVIII-SQ (AAV5-FVIII-SQ). The results from this exciting study are now published in Blood.
April 1, 2020
Welcome to our new website!
Our new website has arrived! We are happy to present our new homepage developed in collaboration with the digital advertising agency MK Media in Gothenburg, Sweden.
February 2, 2020
New Rossix publication in Haemophilia
A new publication from Rossix: Higher potency is obtained with chromogenic substrate (CS) methods and one‐stage (OS) method with SynthAFax vs silica‐based OS methods on analysis of albutrepenonacog alpha (rFIX fused with albumin, rFIX‐FP). We provide an explanation for the discrepancies between the methods.
July 15, 2019
Three Rossix posters at ISTH in Melbourne
Rossix presented three posters related to analysis of Factor IX at the ISTH in Melbourne July 6-10, 2019. Learn more and download the posters here!
June 22, 2016
Publication in collaboration with Novo Nordisk
In an interesting research collaboration Rossix and NovoNordisk found the explanation to why one-stage factor IX clotting assay using silica containing APTT reagents highly overestimate N-glycoPEGylated factor IX activity (Nonacog beta pegol (N9-GP) ). The work was published in Journal for Thrombosis and Haemostasis in May 2016.